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Abstract
Objectives
To investigate 68Ga-TRAP-(RGD)3 hybrid imaging for the in vivo monitoring of αvß3-integrin
expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer.
Materials and Methods
Human breast cancer (MDA-MB-231) xenografts were implanted orthotopically into the
mammary fat pads of n = 25 SCID mice. Transmission/emission scans (53 min to 90 min
after i.v. injection of 20 MBq 68Ga-TRAP-(RGD)3) were performed on a dedicated small ani-
mal PET before (day 0, baseline) and after (day 7, follow-up) a 1-week therapy with the
VEGF antibody bevacizumab or placebo (imaging cohort n = 13; therapy n = 7, control n =
6). The target-to-background ratio (TBR, VOImaxtumor/VOImeanmuscle) served as semiquan-
titative measure of tumor radiotracer uptake. Unenhanced CT data sets were subsequently
acquired for anatomic coregistration and morphology-based tumor response assessments
(CT volumetry). The imaging results were validated by multiparametric ex vivo immunohis-
tochemistry (αvß3-integrin, microvascular density–CD31, proliferation–Ki-67, apoptosis–
TUNEL) conducted in a dedicated immunohistochemistry cohort (n = 12).
Results
68Ga-TRAP-(RGD)3 binding was significantly reduced under VEGF inhibition and decreased
in all bevacizumab-treated animals (ΔTBRfollow-up/baseline: therapy -1.07±0.83, control
+0.32±1.01, p = 0.022). No intergroup difference in tumor volume development between day
0 and day 7 was observed (Δvolumetherapy 134±77 μL, Δvolumecontrol 132±56 μL, p = 1.000).
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Immunohistochemistry revealed a significant reduction of αvß3-integrin expression
(308±135 vs. 635±325, p = 0.03), microvascular density (CD31, 168±108 vs. 432±70, p =
0.002), proliferation (Ki-67, 5,195±1,002 vs. 7,574±418, p = 0.004) and significantly higher
apoptosis (TUNEL, 14,432±1,974 vs. 3,776±1,378, p = 0.002) in the therapy compared to
the control group.
Conclusions
68Ga-TRAP-(RGD)3 hybrid imaging allows for the in vivo assessment of αvß3-integrin
expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer.
Introduction
Hybrid imaging has evolved into an essential diagnostic modality for state-of-the-art tumor
staging in modern clinical oncology, allowing for a non-invasive tumor characterization on
the morphological, functional, and molecular level [1]. While 18F-fluorodeoxyglucose (FDG)
remains the most widely applied tracer in positron emission tomography (PET), the arsenal of
diagnostic radiotracers has been expanded significantly over the last decade [2–5]. The devel-
opment of radiolabeled arginylglycylaspartic acid (RGD) tracers has enabled the specific tar-
geting of αvß3-integrin, an endothelial and tumor cell receptor with a significant role in
neoangiogenesis [6]. Integrins are a family of transmembrane proteins interacting with a vari-
ety of ligands from the extracellular matrix [7]. Mediating cell adhesion and extracellular-to-
intracellular signaling pathways, they have been identified as key players in tumor progression
and metastasis [7]. αvß3-integrin is overexpressed by angiogenic endothelium and tumor cells
and is involved in various angiogenic signaling cascades including the Vascular Endothelial
Growth Factor (VEGF) pathway [8, 9]. VEGF augments endothelial cell migration and adhe-
sion by indirect, receptor-mediated αvß3-integrin activation [9]. Vice versa, inhibition of
VEGF was shown to significantly suppress tumor αvß3-integrin expression in line with a sig-
nificant reduction of microvascular density [10–12]. αvß3-integrin is therefore proposed a
marker of angiogenic activity and a target structure for the in vivo imaging of tumor neoangio-
genesis [8]. Inhibition of the VEGF pathway using the VEGF antibody bevacizumab as either
single or combination therapy has become an established clinical anti-angiogenic treatment
regimen applied in various tumor entities, including non-small-cell lung, colorectal, and breast
cancer [13]. In vivo, intact murine VEGF is not recognized by bevacizumab, while cleaved
murine VEGF can be recognized by this antibody in Western Blots [14].
However, a recent study confirmed the anti-VEGF activity of bevacizumab in murine mod-
els [15]. Accordingly, Wang and colleagues recently demonstrated that bevacizumab exhibits
anti-VEGF activity in human colorectal carcinoma xenografts in mice [16].
RGD radiotracers have been shown to allow for the non-invasive quantification of αvß3-
integrin expression in vivo [6]. Semiquantitative measures of tissue RGD radiotracer uptake
demonstrated excellent correlations with the αvß3-integrin receptor expression as quantified
by ex vivo immunohistochemistry [17, 18]. The selective in vivo imaging of endothelial αvß3-
integrin expression as surrogate of tumor angiogenesis may be limited by αvß3-integrin over-
expressed on tumor cell surfaces [10, 12]. The triple-negative human breast cancer cell line
MDA-MB-231 exhibits only marginal tumor cell αvß3-integrin expression and therefore
potentially facilitates the in vivo imaging of αvß3-integrin expressing tumor vasculature [10,
19]. However, tumors in which αvß3-integrin expression remains predominantly reserved to
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the endothelium require RGD radiotracers with a high target affinity, as whole-tumor αvß3-
integrin expression and therefore whole-tumor radiotracer uptake will remain relatively low.
The novel cyclic radiotracer 68Ga-1,4,7-triazacyclononane-1,4,7-tris[(2-carboxyethyl)(methy-
lenephosphinic acid]) (TRAP)-(RGD)3 may prove advantageous for the in vivo imaging of
tumor models with a low overall αvß3-integrin expression such as MDA-MB-231, as it demon-
strated a more than seven-fold higher in vitro target affinity compared to the monomeric
radiotracers 18F-Galacto-RGD and 68Ga-1,4,7-triazacyclononane-1,4-bis(acetic acid)
(NODAGA)-RGD [20].
The aim of the present study was to investigate the applicability of 68Ga-TRAP-(RGD)3-
PET/CT for the quantitative and longitudinal in vivo imaging of a low αvß3-integrin express-
ing human breast cancer model. We therefore hypothesized that 68Ga-TRAP-(RGD)3-PET/CT
allows for the in vivo monitoring of αvß3-integrin expression as biomarker of anti-angiogenic
therapy effects in orthotopic MDA-MB-231 breast cancer xenografts in mice treated with the
VEGF antibody bevacizumab over the course of one week.
Materials and Methods
The study was approved by the Government of Upper Bavaria Committee of Animal Research
(Gz.: 55.2-1-54-2532-82-2014). It was conducted in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals. All efforts were taken to minimize
animal suffering. The mice were kept in individually-ventilated cages (n = 4 per cage; constant
temperature 26˚C, relative air humidity 65%, 18 room air changes per hour, light-dark-cycle
12 hours). Animals were nourished ad libitum with water and dedicated small animal nutri-
tion. In order to assure environmental enrichment, nest boxes and nestlets were provided.
After tumor cell inoculation, animals were monitored once a day and tumor growth was deter-
mined using a caliper. Weight and tumor growth were noted on a daily basis. Abnormal inac-
tivity was considered to indicate pain and was treated by analgesia (buprenorphin 0.5 mg/kg
body weight s.c.). Imaging was performed under isoflurane anesthesia (2.5% in 1.0 L 100% O2/
min for induction and 1.5% in 1.0 L 100% O2/min for maintenance, respectively). The animals
were euthanized if one of the following conditions were present: no tumor growth, tumor size
>1.5 cm, ulceration of tumors, weight loss >20%, apathy, remarkable defense reaction when
tumors were palpated, remarkable breathing difficulties, lameness, and a non-physiologic
body posture. Animals were euthanized under inhalation anesthesia (5.0% isoflurane in pure
oxygen) by intracardial injection of a saturated potassium chloride solution.
Tumor model and study setup
In a previous study, we confirmed the low tumor cell αvß3-integrin expression of the investi-
gated MDA-MB-231 (ATCC1 HTB-26™, Manassas, VA) cell line by flow cytometry experi-
ments [10]. 3 x 106 MDA-MB-231 cells were resuspended in 0.05 mL of 1:1 Matrigel™ (BD
Biosciences, San Jose, CA) / phosphate-buffered saline (PBS) solution and injected into the
mammary fat pads of n = 25 Severe Combined Immunodeficiency (SCID) mice (age: 7 to 8
weeks; Harlan Laboratories Inc., Indianapolis, IN). After reaching a tumor size of 0.5 cm, the
animals were assigned to either the imaging (n = 13) or the immunohistochemistry cohort
(n = 12).
Imaging cohort (n = 13): The animals were randomly assigned to either the therapy (n = 7)
or the control group (n = 6). After the baseline scan (day 0), animals were treated daily with
either bevacizumab (therapy group; Avastin1, Hoffmann-La Roche AG, Basel, Switzerland; 5
mg/kg body weight) or a volume-equivalent placebo solution (control group; 0.9% sodium
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chloride) for one week (days 1 to 6). The therapeutic agents were injected into the peritoneal
cavity using a 27-gauge needle. On day 7, the follow-up imaging was performed.
Immunohistochemistry cohort (n = 12): In order to exclude competitive blocking effects
between the primary anti-αvß3-integrin antibody used for the immunohistochemical staining
and receptor-bound 68Ga-TRAP-(RGD)3, the ex vivo immunohistochemical validation was
conducted in a separate animal cohort. Analogously to the imaging cohort, mice were ran-
domly assigned to either the therapy (n = 6) or the control group (n = 6), and the above-
described one-week therapy regimen was carried out accordingly. On day 7, the animals were
sacrificed and tumors were explanted and cut in half in order to undergo the immunohisto-
chemical workup. One half was cryopreserved in liquid nitrogen at -196˚C for 1 min and then
stored at -80˚C, while the other half was fixed in formalin. Fig 1 provides an overview of the
study setup.
68Ga-TRAP-(RGD)3
68Ga-TRAP-(RGD)3 was synthesized as described previously [20–22] with slight modifica-
tions. Briefly, 25 μg of the precursor (AVEBETRIN, SCINTOMICS GmbH, Fu¨rstenfeldbruck,
Germany) dissolved in 288 μL 1 M Na-acetate were labelled with 300–400 MBq 68GaCl3 eluted
in 2 mL 0.1 N HCl from a 68Ge/68Ga-generator (IGG100-50M, Eckert & Ziegler Radiopharma
GmbH, Berlin, Germany). After heating for 10 min at 90˚C followed by purification via C18
cartridge the final injection solution was prepared by adjusting the pH with phosphate buffer
to 7.2. Radiochemical purity of each preparation was>98% determined by radio-high perfor-
mance liquid chromatography. The in vivo properties of 68Ga-TRAP-(RGD)3 in mice were
characterized previously, including blocking, metabolite, and biodistribution studies [20].
Imaging protocol
Imaging was performed under isoflurane anesthesia (2.5% in 1.0 L 100% O2/min for induction
and 1.5% in 1.0 L 100% O2/min for maintenance, respectively).
68Ga-TRAP-(RGD)3 (20 MBq
in a total volume of 100 μL) was injected via the lateral tail vein. The animals were then placed
within the aperture of a dedicated small animal PET (Inveon Dedicated PET, Preclinical Solu-
tions, Siemens Healthcare Molecular Imaging, Knoxville, TN) and a 7-minute transmission
scan employing a rotating 57Co source was started 53 min after injection. Transmission scans
were acquired for scatter and attenuation correction. Subsequently, an emission scan (three-
dimensional listmode acquisition) was initiated from 60 to 90 min after radiotracer injection.
Fig 1. Study setup. After the 68Ga-TRAP-(RGD)3-PET/CT baseline scan (day 0), animals of the imaging cohort were treated daily with
either bevacizumab (therapy group) or a volume-equivalent placebo solution (control group) for 6 days. 68Ga-TRAP-(RGD)3-PET/CT follow-
up scan was performed on day 7. Animals of the immunohistochemistry cohort were randomized to a therapy and a control group and
treated analogously to the imaging cohort with either bevacizumab (therapy group) or placebo (control group) for 6 days. On day 7, the
animals of the immunohistochemistry cohort were sacrificed and the tumors were explanted in order to undergo immunohistochemical
workup with regard to αvß3-integrin expression, microvascular density (CD31), proliferation (Ki-67), and apoptosis (TUNEL).
doi:10.1371/journal.pone.0168248.g001
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An unenhanced CT (Somatom Force, Siemens Healthcare, Erlangen, Germany; 35 mAs, 100
kV, slice thickness 0.6 mm; reconstructed in axial, coronal, and sagittal planes) data set in iden-
tical animal position relative to the PET scan was acquired, serving for anatomic coregistra-
tion, tumor localization, and morphology-based assessments of tumor response (CT
volumetry at day 0 and day 7).
Data post-processing and analysis
The PET data sets were analyzed using dedicated post-processing software (Inveon Acquisi-
tion Workplace, Siemens Medical Solutions, Knoxville, TN). Data sets were reconstructed as
static images using OSEM 3D and MAP 3D algorithms with 4 and 32 iterations, respectively.
PET image parameters were as follows: 256 x 256 matrix, 159 slices, slice thickness 0.796
mm, zoom factor 100%, spatial resolution 1.5 mm. PET data sets were normalized and cor-
rected for attenuation and scatter as well as for randoms, dead time, and decay. CT Vol-
umes-of-Interest (VOI) were superimposed on PET images to determine corresponding
volumes for quantification of the PET signal. Fig 2 provides details on VOI selection. The
target-to-background ratio (TBR, Volume-of-Interest (VOImaxtumor/VOImeanmuscle) was
determined as semiquantitative measure of tumor radiotracer accumulation before (day 0)
and after treatment (day 7). As the radiotracer uptake is normalized to a reference tissue
(muscle), TBR is, compared to the standardized uptake value, less sensitive to inter- and
intraindividual variations in mouse weight, radiotracer blood clearance, and radiotracer
dose. Tumor regions with spillover from the urinary bladder were excluded from the analy-
sis. Tumor volumes [μL] at baseline and follow-up were measured by CT volumetry using
the above-mentioned post-processing software. PET and CT data sets were analyzed coregis-
tered as side-by-side examinations.
Fig 2. VOI selection. Images in coronal reconstruction. A: unenhanced CT (tumor indicated by asterisk); B:
unenhanced CT with tumor (green, asterisk) and muscle (violet, arrow) VOIs; C: fused PET and CT data sets;
D: fused PET and CT data sets with tumor (pink, asterisk) and muscle (violet, arrow) VOIs. Tumor and muscle
VOIs selected on the unenhanced CT (B) were superimposed on the PET data sets (D) to allow for a
quantification of the PET signal. Note that tumor regions with significant signal spillover from the urinary
bladder were excluded from the quantitative analysis (D).
doi:10.1371/journal.pone.0168248.g002
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Immunohistochemistry
αvβ3-integrin. After fixation in acetone at a temperature of -20˚C and blocking of endoge-
nous peroxidase (peroxidase blocking reagent; DAKO, Hamburg, Germany), tumor cryosec-
tions (6 μm) were incubated with the primary mouse anti-human integrin αvβ3 monoclonal
antibody (anti-human Integrin αvβ3 LM609, 1:50; Merck Millipore, Darmstadt, Germany) for
2 h. The tissue sections were subsequently treated with a secondary anti-mouse antibody
(Envsion™+ Kit; DAKO, Hamburg, Germany). αvβ3-integrin expression was then visualized
using an AEC-Chromogen (Envsion™+ Kit; DAKO, Hamburg, Germany).
CD31, Ki-67, TUNEL. To assess microvascular density (CD31), tumor cell proliferation
(Ki-67), and apoptosis (TUNEL), formaldehyde-fixed and paraffin-embedded tissue sections
were dewaxed and rehydrated using standard protocols. Expression of CD31 and Ki-67 were
analyzed using the Envsion™+System-HRP AEC/DAB system (DAKO, Hamburg, Germany)
according to the manufacturer’s instructions. After microwave antigen-demasking in a target-
retrieval solution (DAKO, Hamburg, Germany) and peroxidase blocking, tissue specimens
were incubated with the primary anti-CD31 (1:50; ab28364, Abcam, Cambridge, UK) or anti-
Ki-67 (1:100; ab16667, Abcam, Cambridge, United Kingdom) antibodies overnight. Subse-
quently, tissue sections were treated with a secondary anti-rabbit antibody (Envsion™+ Kit;
DAKO, Hamburg, Germany) and expression of CD31/Ki-67 was visualized using an AEC-
chromogen (CD31) or a DAB-chromogen (Ki-67), respectively. Apoptosis was assessed by
TUNEL assays (In situ Cell Death Detection Kit; Sigma-Aldrich, Taufkirchen, Germany).
Fluorescence microscopy at a standard fluorescent filter (520±20 nm; DM 2500, Leica Camera
AG, Wetzlar, Germany) was used to quantify the number of apoptotic cells.
Quantitative immunohistochemical parameters were expressed as the number of positively
stained microvessels (αvβ3-integrin and CD31) or cells (Ki-67 and TUNEL) in ten random
high-power fields at 200x magnification.
CD31/αvβ3-integrin fluorescent double staining. Cryosections were prepared, fixed in
acetone at a temperature of -20˚C for 10 min, air-dried for 20 min, and unspecific binding
sites were blocked with normal goat serum (5% in 1x PBS) for 1 h. Tissue sections were then
treated with the primary anti-CD31 (1:50; Abcam, Cambridge, United Kingdom) and anti-
αvβ3-integrin (LM609: 1:50, Merck Millipore, Darmstadt, Germany) antibodies at 4˚C over-
night. After incubation with dye-conjugated secondary antibodies (goat anti-Mouse IgG Alexa
Fluor 488: 1:500; Abcam, Cambridge, United Kingdom; donkey anti-Rabbit Cy3™: 1:300; Jack-
son ImmunoResearch Inc., West Grove, PA) and nuclear staining (DAPI; 1 μg/mL; Roth,
Karlsruhe, Germany), tissue sections were mounted and coverslipped with Fluoromount™
(Sigma, Taufkirchen, Germany). Images were analyzed using a dedicated fluorescence micro-
scope (DM 2500; Leica Camera AG, Wetzlar, Germany).
Validation of 68Ga-TRAP-(RGD)3 binding specificity in MDA-MB-231
xenografts using autoradiography and immunofluorescence imaging
Target specificity of 68Ga-TRAP-(RGD)3 was validated in two steps. First, we conducted auto-
radiography experiments of radiotracer-incubated tumor sections with and without blocking
of the αvβ3-integrin receptor using a specific antibody (step 1). Second, the specific αvβ3-integ-
rin receptor blocking in the autoradiography experiments was confirmed by secondary immu-
nofluorescence stainings (step 2).
Step 1: For autoradiography, tumor cryosections (6 μm) mounted on glass slides were
unfrozen and dried at room temperature for 2 h. Half number of the slide-mounted tumor sec-
tions were washed with binding buffer (Tris-HCl 50 mM, pH 7.4) and air-dried for 1.5 h. For
the blocking experiments, the remaining half of the slide-mounted tumor sections were
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incubated with the primary anti-αvβ3-integrin antibody (LM609: 1:20, Merck Millipore,
Darmstadt, Germany) for 1 h, then washed with binding buffer (Tris-HCl 50 mM, pH 7.4) and
air-dried for 1.5 h. Subsequently, all slides (without and with αvβ3-integrin receptor blocking)
were incubated with 68Ga-TRAP-(RGD)3 (5 MBq in 50 mL Tris-HCl 50 mM), washed with
binding buffer, and air-dried for 1 h. The slides were then placed on autoradiography imaging
plates (BAS cassette2 2025 imaging plates, Fujifilm, Tokyo, Japan) for 2.5 h, and imaging plates
were subsequently scanned by autoradiography (CR-35-BIO, 25 μm resolution, Elysia-Raytest
GmbH, Straubenhardt, Germany). Image analysis was performed using dedicated post-pro-
cessing software (AIDA image analyzing software V4.50, Elysia-Raytest GmbH, Strauben-
hardt, Germany). Signal intensity (intensity per area; background subtraction) was extracted
in adjacent blocked and unblocked tumor sections. The ratio between unblocked and blocked
tumor sections was calculated.
Step 2: In order to validate the specific αvβ3-integrin receptor blocking in the autoradiogra-
phy experiments, we performed αvβ3-integrin fluorescent stainings as described above. Briefly,
the same tumor sections used for the autoradiography were incubated with the primary anti-
αvβ3-integrin (LM609: 1:50, Merck Millipore, Darmstadt, Germany) and dye-conjugated sec-
ondary antibodies (goat anti-Mouse IgG Alexa Fluor 488: 1:500; Abcam, Cambridge, United
Kingdom; donkey anti-Rabbit Cy3™: 1:300; Jackson ImmunoResearch Inc., West Grove, PA)
immediately after step 1. The tumor slides were then analyzed using a preclinical optical imag-
ing system (In-Vivo FX PRO, Bruker Corp., Billerica, MA) with a charge-coupled device cam-
era (excitation filter 480 nm, emission filter 535 nm, field-of-view 200 mm, focal plane 11 mm,
2x x-binning, 2x y-binning, 130 x 130 ppi). Fluorescent stainings were analyzed visually and
interpreted qualitatively.
Statistical analysis
The statistical analysis was performed using SPSS 23 for Windows (IBM Corp., Armonk, NY).
Descriptive statistical data were expressed as arithmetic means with standard deviations at
95% confidence intervals. Wilcoxon/Mann-Whitney U tests were applied for intra- and inter-
group comparisons of the quantitative parameters. Linear correlations between non-normally
distributed variables were assessed by Spearman’s test. Autoradiographic signal intensities in
unblocked and adjacent blocked tumor sections were compared using a paired student’s t test.
Statistical significance was assumed for p-values <0.05.
Results
68Ga-TRAP-(RGD)3 binding
68Ga-TRAP-(RGD)3 binding was significantly reduced following VEGF inhibition (mean
ΔTBRfollow-up/baseline: therapy -1.07±0.83, control +0.32±1.01; p = 0.022). We observed a signifi-
cant decline of TBR in all animals of the therapy group (from TBRtherapy-baseline 3.04±0.95 to
TBRtherapy-follow-up 1.97±0.29; p = 0.018). In the control group, TBR developed omnidirection-
ally, with an increase in n = 5 animals (from TBRcontrol-baseline 2.98±0.92 to TBRcontrol-follow-up
3.30±0.63; p = 0.500). There was no significant difference in baseline TBR between the therapy
and the control group (TBRtherapy-baseline 3.04±0.95, TBRcontrol-baseline 2.98±0.92; p = 0.836).
Table 1 provides individual TBR values of the animals of the therapy and the control group.
TBR values of the therapy and control group are displayed as boxplots in Fig 3. Representative
PET/CT images of a tumor before and after VEGF inhibition are shown in Fig 4.
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Tumor volume
Contrary to the changes in αvß3-integrin expression detected by
68Ga-TRAP-(RGD)3-PET,
there was no significant intergroup difference in tumor volume development over the course
of the experiment (Δvolumetherapy 134±77 μL, Δvolumecontrol 132±56 μL; p = 1.000). There was
no significant difference in baseline tumor volumes between therapy and control group (volu-
metherapy-baseline 289±162 μL, volumecontrol-baseline 248±89 μL; p = 0.628). No significant correla-
tion between tumor volumes and TBR values at baseline and follow-up was observed
(Spearman’s ρ -0.23; p = 0.261). Table 1 displays individual tumor volumes before and after
treatment.
Immunohistochemistry
Immunohistochemistry revealed a significant reduction of αvß3-integrin expression (308±135
vs. 635±325, p = 0.03), microvascular density (CD31, 168±108 vs. 432±70, p = 0.002), prolifera-
tion (Ki-67, 5,195±1,002 vs. 7,574±418, p = 0.004), as well as significantly higher apoptosis
(TUNEL, 14,432±1,974 vs. 3,776±1,378, p = 0.002) in the therapy compared to the control
group. Individual quantitative immunohistochemical parameters are summarized in Table 2.
The immunohistochemical data are summarized by boxplots in Fig 5. Representative immu-
nohistochemical tumor sections of the therapy and control group are shown in Fig 6.
CD31/αvβ3-integrin fluorescent double stainings confirmed the predominantly endothelial
αvβ3-integrin expression in the investigated MDA-MB-231 human breast cancer xenografts
(Fig 7). The combined autoradiography and immunofluorescence imaging experiments con-
firmed the target specificity of 68Ga-TRAP-(RGD)3 and demonstrated that binding of the pri-
mary anti-αvβ3-integrin antibody is effectively blocked by receptor-bound radiotracer (Fig 8).
Quantitative assessment in autoradiography revealed an intensity ratio of 2.71 ± 1.54 between
Table 1. Imaging cohort: individual TBR values and tumor volumes for therapy and control group.
No. Group (T/C)a TBRBaseline TBRFollow-up ΔTBR VolBaseline [μL] VolFollow-up [μL]
1 T 2.5 2.0 -0.5 207 291
2 T 3.4 1.6 -1.8 527 739
3 T 4.9 2.5 -2.4 425 606
4 T 2.2 1.9 -0.3 193 430
5 T 2.3 2.1 -0.2 241 269
6 T 2.6 1.7 -0.9 51 157
7 T 3.4 2.0 -1.4 378 469
mean±SDb 3.04±0.95 1.97±0.29 -1.07±0.83c 289±162 423±203d
11 C 2.5 3.6 +1.1 182 298
12 C 2.0 2.4 +0.4 148 200
13 C 2.1 3.4 +1.3 194 364
14 C 4.3 2.8 -1.5 379 562
15 C 3.4 3.4 0 313 498
16 C 3.6 4.2 +0.6 273 356
mean±SDb 2.98±0.92 3.30±0.63 +0.32±1.01c 248±89 380±132d
aT = therapy, C = control;
bSD = standard deviation;
cp = 0.02 (therapy vs. control;
dp = 1.000 (Δvolumetherapy vs. Δvolumecontrol)
doi:10.1371/journal.pone.0168248.t001
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unblocked and blocked tumor sections (p = 0.001). Detailed quantitative data for the autoradi-
ography blocking experiments are provided in Table 3.
Discussion
In this experimental study, 68Ga-TRAP-(RGD)3-PET/CT allowed for the non-invasive moni-
toring of anti-angiogenic effects in a low αvß3-integrin expression orthotopic human breast
cancer model in mice, generating complementary and additional information to morphology-
based tumor response assessments. 68Ga-TRAP-(RGD)3 binding was significantly reduced fol-
lowing VEGF inhibition, analogously to the significant suppression of αvß3-integrin expres-
sion observed in the immunohistochemistry cohort. In untreated animals, 68Ga-TRAP-
(RGD)3 uptake increased over the course of the experiment and αvß3-integrin expression was
found to be significantly higher.
Our observations are in accordance with a previous study investigating a 68Ga-labeled pegy-
lated RGD dimer probe for monitoring the early anti-angiogenic effects of an endostatin
therapy in heterotopic human lung cancer xenografts in mice [23]. Validated by ex vivo immu-
nohistochemistry, the authors found the RGD radiotracer uptake to be significantly reduced
following anti-angiogenic therapy, reflecting tumor response significantly earlier than
Fig 3. TBR at baseline and follow-up. Note the significant (p = 0.018) decrease in TBR in the therapy group between day 0 and day 7. No
significant (p = 0.500) change in TBR was observed in the control group. There was no significant (p = 0.836) difference in baseline TBR
between the therapy and the control group.
doi:10.1371/journal.pone.0168248.g003
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18F-FDG-PET. Contrary results were reported by Rylova et al. who studied 68Ga-NODA-
GA-RGD for the in vivo monitoring of a bevacizumab monotherapy in human squamous cell
carcinoma xenografts in mice [12]. Despite a reduced αvß3-integrin expression under VEGF
inhibition, they observed an increased binding of 68Ga-NODAGA-RGD in the investigated A-
431 xenografts. Rylova et al. therefore concluded that RGD radiotracer uptake might not nec-
essarily reflect the changes in αvß3-integrin expression on the molecular level. They hypothe-
sized that bevacizumab may activate αvß3-integrin, causing a higher affinity to
68Ga-
NODAGA-RGD and consequently increased radiotracer uptake in vivo. Assuming a high-
affinity state of αvß3-integrin however, one would expect an increased binding of the primary
anti-αvß3-integrin antibody used in the immunohistochemical stainings and consequently
false-high αvß3-integrin levels. However, in line with our results, the authors found a reduced
αvß3-integrin expression in the therapy group. In addition, VEGF is known to indirectly acti-
vate αvß3-integrin [9]. It therefore becomes unlikely that VEGF inhibition also causes αvß3-
integrin activation. The validation experiments in the present study revealed that binding of
the primary anti-αvß3-integrin antibody used in the immunohistochemical analysis is effec-
tively blocked by receptor-bound radiotracer. Our results suggest that intraindividual immu-
nohistochemical validation, i.e., αvß3-integrin staining of tumors previously exposed to RGD
radiotracers, may only be of limited value. We therefore conclude that the assessment of the
αvß3-integrin receptor status parallel to RGD PET imaging requires a dedicated immunohis-
tochemistry animal cohort. Competitive blocking effects between receptor-bound radiotracer
and the αvß3-integrin-specific antibody may also be a possible explanation for the contrary
observations reported by Rylova et al. [12].
Fig 4. Representative coregistered 68Ga-TRAP-(RGD)3-PET/CT data sets of one animal from the
therapy group. Animal in prone position. Top row: unenhanced CT data sets at baseline (A) and follow-up
(B). The tumor placed in the left mammary fat pad is circled in red. Bottom row: PET data sets at baseline (C)
and follow-up (D). White arrows and asterisks indicate the tumor. Note the significant decrease in tumor
radiotracer uptake between baseline (day 0, C) and follow-up (day 7, D). The unenhanced CT data sets (A—
baseline; B—follow-up) served for anatomic colocalization and allowed for the exclusion of relevant tumor
necrosis.
doi:10.1371/journal.pone.0168248.g004
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Bevacizumab is the humanized form of mouse VEGF Mab A4.6.1 and therefore shows no
cross-reactivity with circulating murine VEGF [24]. Nevertheless, ex vivo immunohistochem-
istry revealed significant anti-angiogenic effects of bevacizumab in the investigated MDA-MB-
231 human breast cancer model in mice, as indicated by the suppression of endothelial marker
CD31 and αvß3-integrin expression under therapy. In line with these findings, significant anti-
angiogenic effects of bevacizumab have also been observed in various other in vivo models of
human cancer in murines [16, 25, 26]. Although not targeting murine VEGF, bevacizumab
binds to tumor-derived human VEGF when applied in vivo [24]. As only human tumor cells
and no stromal/endothelial cells were injected into the mammary fat pads of the nude mice in
our study, the vasculature of the xenografts must be of murine origin [27]. However, as shown
by Millauer et al. [28], the murine VEGF receptor 2 (= flk-1) shows a high affinity for human
VEGF, resulting in upregulation of angiogenesis. Consequently, in vivo blocking of human
VEGF using a human VEGF-specific monoclonal antibody (2C3) showed significant anti-
angiogenic effects in MDA-MB-231 human breast cancer xenograft-bearing mice [29]. There-
fore, bevacizumab exhibits significant anti-angiogenic effects in human tumor xenograft mod-
els in which angiogenesis is also driven by human VEGF [24]. Accordingly, Liang et al. found
that the response of human cancer xenografts to bevacizumab is highly dependent on the
grade of host stroma invasion and the presence of stroma-derived VEGF [30]. The authors
demonstrated that human tumor xenografts with low murine stroma invasion show a better
response to bevacizumab than those with high murine stroma invasion, as the angiogenic
response predominantly relies on tumor-derived, human VEGF [30]. Bevacizumab thus
blocked the tumor-derived but not the host-derived VEGF in the MDA-MB-231 human breast
Table 2. Immunohistochemistry cohort: individual values of immunohistochemical parameters for therapy and control group. Subsequent to fol-
low-up imaging on day 7, tumors were explanted to undergo multiparametric immunohistochemistry with regard to αvß3-integrin expression, microvascular
density (CD31), proliferation (Ki-67), and apoptosis (TUNEL). Results are expressed as mean number of positively-stained microvessels (αvß3-integrin and
CD31) or cells (Ki-67 and TUNEL) per ten high-power fields at 200x magnification.
No. Group (T/C)a αvß3-integrin CD31 Ki-67 TUNEL
1 T 240 35 5,763 15,522
2 T 175 136 6,075 16,623
3 T n/a 129 4,669 16,286
4 T 328 328 5,461 11,889
5 T 267 267 5,800 12,795
6 T 528 114 3,404 13,477
mean ± SDb 308±135 168±108 5,195±1,002 14,432±1,974
7 C 730 527 7,422 2,316
8 C 375 491 7,409 2,354
9 C 431 440 n/a 5,255
10 C 564 391 8,006 3,730
11 C 1,248 407 7,992 5,527
12 C 464 335 7,039 3,476
mean ± SDb 635±325c 432±70d 7,574±418e 3,776±1,378f
aT = therapy, C = control;
bSD = standard deviation;
cp = 0.03,
dp = 0.002,
ep = 0.004,
fp = 0.002 (therapy vs. control)
doi:10.1371/journal.pone.0168248.t002
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cancer xenografts investigated in the present study. This is in support of the defined study pur-
pose, which was not to understand the host-specific VEGF response but to investigate a novel,
αvß3-integrin-targeted radiotracer for monitoring anti-angiogenic effects in a small animal
model of human breast cancer. Our findings indicate that human, tumor-derived VEGF sub-
stantially triggers neovascularization in the investigated MDA-MB-231 human breast cancer
model in mice and that a one-week bevacizumab monotherapy can be successfully applied to
inhibit angiogenesis in this particular tumor model. However, it has to be acknowledged that
residual, pro-angiogenic effects caused by uninhibited murine VEGF may still be present.
Our results confirm the applicability of 68Ga-TRAP-(RGD)3 in the investigated, low αvß3-
integrin expression tumor model. In a rodent model of myocardial infarction however, 68Ga-
TRAP-(RGD)3 allowed for the assessment of αvß3-integrin expression as imaging biomarker
of myocardial repair, but, despite the higher target affinity in vitro [20], did not show a higher
uptake than 68Ga-NODAGA-RGD or 18F-Galacto-RGD [31]. It can thus be postulated that the
individual performance of different RGD radiotracers may vary depending on the investigated
microstructures and tumor models. In the investigated MDA-MB-231 xenograft model, 68Ga-
TRAP-(RGD)3 allowed for a robust and reproducible dual time-point in vivo imaging and
generated moderate-to-good TBR.
αvß3-integrin has recently gained attention as potential imaging target for the non-invasive
in vivo characterization of the tumor microenvironment, and first clinical studies investigating
radiolabeled RGD compounds in humans have been published [17, 32]. In particular, the in-
human use of RGD-based radiotracers proved to be safe with tumor-specific uptake profiles
Fig 5. Quantitative immunohistochemical parameters for the therapy and control group. Note the
significant (p = 0.03) suppression of αvß3-integrin expression in the bevacizumab-treated group (A). Also note
the significantly (p<0.01) lower microvascular density (CD31, B), proliferation (Ki-67, C), as well as the
significantly (p = 0.002) higher apoptosis (TUNEL, D) in the therapy compared to the control group.
doi:10.1371/journal.pone.0168248.g005
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Fig 6. Representative tumor sections of the therapy and the control group. Note the lower αvß3-integrin
expression (A vs. B), microvascular density (CD31, C vs. D), proliferation (Ki-67, E vs. F) and the higher
apoptosis (TUNEL, G vs. H) in the therapy compared to the control group
doi:10.1371/journal.pone.0168248.g006
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[6, 33]. A recent clinical study even demonstrated the potential of combined functional param-
eters of 68Ga-NOTA-RGD- and 18F-FDG-PET/CT for the non-invasive molecular phenotyp-
ing of human breast cancer [34]. The combination of both radiotracers allowed for the
distinction of breast cancer subtypes with regard to the receptor status (i.e., expression of the
estrogen receptor, progesterone receptor, and Human Epidermal Growth Factor Receptor 2),
although the underlying mechanisms still need to be identified. Therefore, the clinical transla-
tion and routine use of RGD-based hybrid imaging are likely to increase within the next years.
The present study may provide a preclinical basis for future clinical studies investigating RGD-
based hybrid imaging for monitoring therapy response to molecular cancer therapies. The
expression of the αvß3-integrin receptor and its distribution within the tumor (endothelial vs.
cellular) should be assessed prior to clinical RGD-based hybrid imaging. This will help clini-
cians to interpret the imaging results as PET imaging is limited in its ability to distinguish
between signal derived from tumor cells and signal derived from the tumor microenviron-
ment. In the future, it will be of particular interest to investigate RGD PET-derived imaging
biomarkers in correlation to clinical end points such as progression-free and overall patient
survival. RGD-based hybrid imaging may allow for a non-invasive real-time molecular pheno-
typing of breast cancer under anti-angiogenic treatment, adding complementary molecular
imaging biomarkers of therapy response to morphology-based and functional tumor response
assessments. As part of multimodal imaging protocols, RGD-based hybrid imaging may help
to identify patients who potentially benefit from targeted treatment regimens and therefore
contribute to a tailored, personalized cancer therapy.
Limitations
We acknowledge several limitations of the study. First, 68Ga-TRAP-(RGD)3 showed a renal
clearance with impaired visualization of lesions adjacent to the urinary system, which is a
known limitation of RGD radiotracers [6]. Accordingly, tumor regions with spillover from
radiotracer in the urinary bladder were not included for the analysis. However, this is a com-
mon difficulty with many radiolabeled peptides, especially when labeled with short half-life
radionuclides. Second, RGD radiotracers are small molecules with potential extravasation and
may therefore also bind to αvß3-integrin expressed by tumor cells. It cannot be quantified to
what degree the RGD radiotracer is bound by the endothelium and to what degree the RGD
Fig 7. αvß3-integrin/CD31 fluorescent double stainings. A— αvß3-integrin; B—CD31; C—overlay of A and B. Fluorescent double
stainings demonstrated a significant coexpression (C) of αvß3-integrin and the endothelial receptor CD31 and therefore confirmed the
predominantly endothelial expression of αvß3-integrin in the investigated tumor model. No relevant tumor cell αvß3-integrin expression was
detected.
doi:10.1371/journal.pone.0168248.g007
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radiotracer is bound by the tumor cells. However, we were able to show that αvß3-integrin
expression is predominantly reserved to the endothelium in the investigated tumor model and
that the MDA-MB-231 tumor cells only exhibit marginal αvß3-integrin expression [10]. Thus,
our experiments confirmed that there is no relevant αvß3-integrin expression in the extravas-
cular compartment. Nevertheless, subtle enhanced permeability and retention-mediated
effects as well as marginal radiotracer binding to the tumor cells cannot be completely
Fig 8. Validation of 68Ga-TRAP-(RGD)3 binding specificity in MDA-MB-231 human breast cancer
xenografts. Top row (A and B): autoradiography of 68Ga-TRAP-(RGD)3-incubated MDA-MB-231 tumor
sections (arrows) without blocking (A) and after (B) blocking of the αvß3-integrin receptor using a specific
antibody. Bottom row (C and D): the same tumor sections (arrows) scanned by optical fluorescence imaging
after additional αvß3-integrin-specific immunofluorescence stainings. C/A and D/B show identical tumor
sections. SI = signal intensity, a.u. = arbitrary units. 68Ga-TRAP-(RGD)3 binding is significantly reduced after
specific blocking of the αvß3-integrin receptor (B vs. A). The immunofluorescence stainings confirmed the
successful αvß3-integrin receptor blocking in the autoradiography experiments (C and D). Note the
complementary binding of the immunofluorescence staining and 68Ga-TRAP-(RGD)3 (C vs. A and D vs. B),
indicating that binding of the primary αvß3-integrin-specific antibody is effectively blocked by receptor-bound
radiotracer.
doi:10.1371/journal.pone.0168248.g008
68Ga TRAP (RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression
PLOS ONE | DOI:10.1371/journal.pone.0168248 December 19, 2016 15 / 19
excluded. However, these would be present to the same degree in both therapy and control
group with no significant impact on whole-tumor TBR. Third, although overexpressed by
angiogenic endothelium, αvß3-integrins are expressed ubiquitously, e.g., in the gut and the
liver, hence compromising the assessment of tumor TBR by elevated background signal and
spillover [6]. Therefore, the respective tumor VOI needs to be selected accordingly. Fourth,
the investigation of additional αvß3-integrin-targeted radiotracers would allow for a side-by-
side comparison of binding specificity and tumor signal in the examined MDA-MB-231
model of breast cancer.
Conclusions
68Ga-TRAP-(RGD)3 proved to be applicable for the longitudinal in vivo monitoring of αvß3-
integrin expression as surrogate of neoangiogenesis in the investigated MDA-MB-231 xeno-
grafts in which αvß3-integrin expression remains predominantly reserved to the endothelium.
68Ga-TRAP-(RGD)3 allowed for a robust and reproducible dual time-point in vivo imaging
and, despite a low overall αvß3-integrin expression, generated moderate-to-good TBR. It can
be concluded that 68Ga-TRAP-(RGD)3 allows for the in vivo imaging of tumor models with
low overall αvß3-integrin expression.
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